Результаты поиска

Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil.

PurposeThe COVID-19 pandemic remains a public health emergency of global concern. Determinants of mortality in the general population are now clear, but specific data on patients with cancer remain limited, particularly in Latin America.Materials and methodsA longitudinal multicenter cohort study of patients with cancer and confirmed COVID-19 from Oncoclínicas community oncology practice in Brazil was conducted. The primary end point was all-cause mortality after isolation of the SARS-CoV-2 by Real-Time Polymerase Chain Reaction (RT-PCR) in patients initially diagnosed in an outpatient environ

Совпадение в полном тексте источника
… All suspicious and SARS-CoV-2 confirmed cases were part of a proactive surveillance program with daily monitoring performed by Oncoclínicas personnel and direct communications with the medical oncologist to collect follow-up data, given the decentralized care across multiple institutions. … Clinical management decisions (outpatient care, hospitalization, and intensive care unit [ICU] admission) were made by the primary oncologists together with local medical teams at each site. …

Trends in overall survival and costs of multiple myeloma, 2000-2014.

Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive

Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.

AimThe purpose of this study was to assess the prescription of epoetins and consumption of health care resources (in terms of drug treatments) in naïve patients with hematological malignancies in a real-world setting; in particular, we compared the results between reference product and biosimilar products.MethodsAn observational retrospective study based on administrative and laboratory databases of three local health units was conducted. All adults diagnosed with hematological malignancies and who had received at least one epoetin (either reference product or biosimilars) prescription for the

Bisphosphonate and medication induced necrosis of jaws.

The bisphosphonates are prescribed drugs to prevent bone resorption particularly in patients having certain malignancies. However, there is a potential risk of osteonecrosis of jaws in patients receiving dental treatment. Therefore, it is of interest to evaluate the chances of osteonecrosis in patients referred for management of osteonecrosis in whom dental treatment was carried out by the referring dental professionals. Hence, 86 patients were studied, where 18 patients had developed osteonecrosis particularly after dental extraction of which 13 patients were having underlying malignancy. We

Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025).

Palliative care is, according to the World Health Organization (WHO), "a global ethical responsibility" and crucial to person-centered healthcare, for the relief of physical and psychological symptoms and social and spiritual suffering, impacting the improvement of the quality of life not only of pediatric and adult patients dealing with life-threatening illnesses, but also of their families. Despite the growing recognition of palliative care in the hematological setting and the increase in the number of publications on the subject, the available data are still scarce and limited. The objectiv

Совпадение в полном тексте источника
… While there was no feedback in the control group, in the intervention group, oncologists and family members received printed reports summarizing the PROs, and emails were sent to oncologists when certain scores were exceeded. … End-of-life care for blood cancers: a series of focus groups with hematologic oncologists J Oncol Pr 10 2014 e396 e403 10.1200/JOP.2014.001537 PMC5706135 25294393 18 Shaulov A. Aviv A. Alcalde J. Zimmermann C. …

Osteosarcoma of the appendicular skeleton in dogs: consensus and guidelines.

Osteosarcoma (OSA) in dogs poses a clinical challenge to veterinary practitioners across the globe. As knowledge evolves, so too do clinical practices. However, there remain uncertainties and controversies. There is value for the veterinary community at large in the generation of a contemporary wide-ranging guideline document. The aim of this project was therefore to assimilate the available published knowledge into a single accessible referenced resource and to provide expert clinical guidance to support professional colleagues as they navigate current OSA challenges and controversies. Primar

Совпадение в полном тексте источника
… Experienced oncologists will rely on the combination of clinical, radiological and cytological findings, and knowledge of endemic pathogens which might radiographically mimic OSA. … Attitudes toward limb amputation vary among oncologists, general practitioners and pet owners. …

Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors.

The incidence of cancer-associated thrombosis has increased in recent years. While the association between venous thromboembolism (VTE) and chemotherapy is well established, there is no clear link between immune checkpoint inhibitors (ICIs) and VTE risk. Many risk assessment models (RAMs) have been developed to identify high-risk patients who need prophylaxis. However, these models are validated in patients undergoing chemotherapy, while they are scarce in those receiving immunotherapy. Moreover, the mechanisms linking ICIs to thrombosis are still a matter of debate. They include the upregulat

ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer.

BackgroundFinancial toxicity, defined as both the objective financial burden and subjective financial distress from a cancer diagnosis and its treatment, is a topic of interest in the assessment of the quality of life of patients with cancer and their families. Current evidence implicates financial toxicity in psychosocial, economic and other harms, leading to suboptimal cancer outcomes along the entire trajectory of diagnosis, treatment, supportive care, survivorship and palliation. This paper presents the results of a virtual consensus, based on the evidence base to date, on the screening an

Совпадение в полном тексте источника
… These consensus statements apply to a wider range of health systems offering medical oncologists and other clinicians and health professionals a more comprehensive understanding of the problem as well as approaches to alleviate this burden. … Oncologist. 2021;26(1):e142–e152. doi: 10.1002/onco.13544. 10. Doshmangir L., Hasanpoor E., Abou Jaoude G.J., et al. Incidence of catastrophic health expenditure and its determinants in cancer patients: a systematic review and meta-analysis. …

Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review.

Social determinants of health (SDHs) have been reported as relevant factors responsible for health inequity. We sought to assess clinical data from observational studies conducted in the United States evaluating the impact of SDHs on the outcomes of patients with hematologic malignancies. Thus, we performed a systematic review in 6 databases on 1 September 2021, in which paired reviewers independently screened studies and included data from 41 studies. We assessed the risk of bias using the Joanna Briggs Institute appraisal tools and analyzed the data using a descriptive synthesis. The most co

Совпадение в полном тексте источника
… Shanafelt 29 showed that patients treated by hematologists/oncologists who specifically focused on their specific malignancy had superior OS than those treated by general hematologists/oncologists. … Oncologist. 2011;16(8):1082–1091. doi: 10.1634/theoncologist.2011-0126. 20. Al-Ameri A, Anand A, Abdelfatah M, et al. Outcome of acute myeloid leukemia and high-risk myelodysplastic syndrome according to health insurance status. …

Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology.

Pleiotropy in biological systems and their targeting allows many pharmaceuticals to be used for multiple therapeutic purposes. Fully exploiting the therapeutic properties of drugs that are already marketed would be highly advantageous. This is especially the case in the field of oncology, where the ineffectiveness of typical anticancer agents is a common issue, while the development of novel anticancer agents is a costly and particularly time-consuming process. Octreotide and chloroquine are two pharmaceuticals that exhibit profound antitumorigenic activities. However, the current therapeutic

Совпадение в полном тексте источника
… Conclusion Exploiting the repositionability of distinct commercially available pharmaceuticals and/or the complete therapeutic potential of agents that are currently clinically underrated may be important strategies for adding “novel” anticancer drugs to the arsenal of oncologists. … the treatment of SLE and lupus nephritis Nat Rev Nephrol 2011 7 12 718 729 22009248 10.1038/nrneph.2011.150 11 Papanagnou P Baltopoulos P Tsironi M Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists …

Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly.

The Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Elderly was elaborated by nutritionists, nutrologists and hematologists physicians from 15 Brazilians reference centers in hematopoietic stem cell transplantation, in order to emphasize the importancy of nutritional status and the body composition during the treatment, as well as the main characteristics related to patient's nutritional assessment. Establishing the consensus, we intended to improve and standardize the nutritional therapy during the hematopoietic stem cell transplantation. The Consensus was approved

Совпадение в полном тексте источника
… Data from the Instituto Nacional do Câncer José Alencar Gomes da Silva (INCA) show that, with the increase in population aging in recent decades, there was also an exponential increase in the incidence of cancer in the Brazilian elderly population, ( 6 ) and this is a major challenge faced by oncologists … Oncologist. 2014;19(10):1056–1068. doi: 10.1634/theoncologist.2014-0180. Review. 64. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. …

Tumor-Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development.

Despite advances in novel therapeutic modalities, such as molecularly targeted agents and immunotherapies, the probability of success in Phase III oncology trials remains low. This study quantitatively characterized success probabilities of Phase III trials in oncology drug development and evaluated the factors associated with trial success. Phase III interventional oncology drug trials registered at ClinicalTrials.gov between 2007 and 2023 with publicly available primary endpoint results were included. Trial success was defined as the achievement of at least one primary endpoint, and tumor-sp

Оценка риска и прогнозирование самоубийств у нескольких пациентов с миэломой.

ЦЕЛЬ: Несмотря на успехи в лечении, позволившие выжить, множество миеломы (ММ) по-прежнему является тревожным диагнозом со значительными последствиями для здоровья, включая повышенный риск самоубийства. Целью этого исследования является изучение риска самоубийств среди пациентов с ОМ и разработка модели прогнозирования для выявления лиц с высокой степенью риска. Методы: Мы проанализировали 83,333 Случаи MM из последней базы данных наблюдения, эпидемиологии и конечных результатов (SEER)2001-2020) для выявления предсказателей риска самоубийства и разработки предсказуемых номограмм. Эта группа бы

Совпадение в полном тексте источника
… Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol : official journal of the American Society of Clinical Oncology. 1998;16(4):1594–600. 30. Preti E, Di Mattei V, Perego G, Ferrari F, Mazzetti M, Taranto P, Di Pierro R, Madeddu F, Calati R. … Patient-oncologist alliance as protection against suicidal ideation in young adults with advanced cancer. Cancer. 2014;120(15):2272–81. …

Temporal trends and determinants of inpatient palliative care utilization among hospitalized patients with acute myeloid leukemia: a retrospective cross-sectional study.

BackgroundAcute myeloid leukemia (AML) remains an aggressive malignancy, despite advancements in diagnosis and treatment. Early integration of palliative care has been shown to alleviate symptom burden and enhance quality of life among patients and their caregivers. However, palliative care remains underutilized, especially in hematologic malignancies. This study aims to determine the rate of inpatient palliative care utilization among hospitalized patients with AML and to identify predictors of inpatient palliative care utilization.MethodsThis retrospective study utilized data extracted from

Совпадение в полном тексте источника
… El-Jawahri et al. highlighted some of these barriers: prognostic uncertainty of hematologic malignancies, a strong curative-intent mindset, and, interestingly, a misconception of the purpose of palliative care among oncologists [ 18 ]. … With advancements in novel therapeutic strategies for hematologic malignancies, including AML, many of which lead to sustained remission even in cases of relapsed or refractory disease, oncologists may equate palliative care with end-of-life care, fearing they have failed the patient and their families …

Real-World Outcomes of Incurable Cancer Patients Treated with Unlisted Anticancer Treatments in an Academic Center in Quebec, Canada.

Medical oncology is a rapidly evolving field, with new medications being discovered yearly, contributing to increased survival rates. However, accessing drugs in a timely manner can be challenging. In Quebec, Canada, a physician can prescribe an unlisted anticancer treatment through a regulated pathway under exceptional circumstances. We conducted a quality improvement study describing the outcomes of incurable cancer patients receiving unlisted anticancer therapy at the Jewish General Hospital between 2018 and 2019. Though our study did not include a comparator arm, unlisted anticancer therap

Radiation Therapy for Plasma Cell Disease of the Brain and Skull: Poor Palliation and Survival After Treatment for Central Nervous System Involvement.

PurposeMyeloma lesions of the head can present with central nervous system (CNS) involvement (leptomeningeal disease or brain metastasis), cranial neuropathy (CN), or impending neurologic involvement (INI). We analyzed response and survival after palliative radiation therapy (RT) to the brain and/or skull for myeloma lesions to determine whether CNS involvement fared worse than other RT indications.Methods and materialsWe retrospectively analyzed 54 palliative RT courses administered at our institution from 2008 to 2019. Eleven courses were administered for CNS disease, 28 for CN, and 15 for I

Совпадение в полном тексте источника
… Radiation dose, fractionation, and treatment fields were at the discretion of the treating radiation oncologist. Treatment characteristics and outcomes are included in Table 2 . … Thus, when evaluating a patient with myeloma involving the head, identifying the extent and symptoms of disease can help radiation oncologists determine whether treatment may benefit the patient and, if so, what dose to prescribe. …

Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma.

This needs-assessment aimed to identify clinical challenges faced by hematologists and hematology nurses in the diagnosis, treatment, and management of multiple myeloma, as well as contextual barriers hindering optimal care of patients with multiple myeloma. This manuscript focuses on key findings in relation to decision-making regarding new treatment options. A mixed methods study consisting of qualitative (from semistructured interviews) and quantitative data (from an online survey) was conducted in 8 European countries among hematologists and hematology nurses. The triangulated data led to

Совпадение в полном тексте источника
… (Hemato-oncologist, Germany) Contextual barriers to the integration of new agents into clinical practice Participants identified contextual barriers that were external to their own role, but did however impact their ability to optimally treat and manage patients with MM. … As an example, in a previous needs assessment across 7 countries, including 5 of the European countries in this study (France, Germany, Italy, Spain, and the UK), oncologists caring for patients with colorectal cancer reported similar challenges in relation to optimal sequential use of treatment choices …

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.

BackgroundCritically reviewing the design, endpoints, and results of clinical trials can be challenging to health care professionals. This paper will review the basic methods of presenting clinical outcomes in randomized trials and will focus on the number needed to treat (NNT) concept. NNT will then be applied to the case of bone-targeted therapies denosumab and zoledronic acid, which are used for the prevention of skeletal-related events (SREs) in a variety of disease sites.MethodsA Medline search was performed to identify randomized trials comparing denosumab to zoledronic acid for the prev

Совпадение в полном тексте источника
… The trial data also suggest that oncologists can expect slightly more cases of ONJ and hypocalcemia with denosumab in patients with breast and prostate cancers [ 7 , 26 ]. However, this would be compensated with fewer cases of acute drug reactions and renal toxicity. … Oncologist. 2004;9(Suppl 4):14–27. doi: 10.1634/theoncologist.9-90004-14. 4. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. …

Dreaming of a better future: drug development in myeloma.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the management of multiple myeloma has made it easier for patients who do not have to come to the hospital for chemotherapy infusions. However, many barriers are associated with oral chemotherapy, and one of them is a misinterpretation of instruction which can have deleterious effects. In this case report, we pr

Совпадение в полном тексте источника
… The availability of oral chemotherapy agents has led many oncologists to transition patients to oral regimens. …